Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Eli Lilly resolves lobbyist's sex discrimination lawsuit

Published 06/29/2021, 02:58 PM
Updated 06/29/2021, 03:01 PM
© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo
LLY
-

By Dan Levine and Marisa Taylor

(Reuters) - Eli Lilly & Co (N:LLY) has resolved a lawsuit filed in March by a former top lobbyist who accused a high-ranking executive and another senior manager of engaging in sexual discrimination, harassment and retaliation against women in its Washington, D.C., office, according to a court filing on Monday.

The suit, filed in federal court in Washington by in-house lobbyist Sonya Elling alleged that a Lilly senior vice president, Leigh Ann Pusey, repeatedly demeaned Elling and other women, and eventually forced Elling to resign https://www.reuters.com/article/us-usa-pharmaceuticals-elililly-suit-exc/exclusive-ex-lobbyist-sues-eli-lilly-alleging-sexual-discrimination-harassment-idUSKBN2BJ0KM.

Pusey, senior vice president of corporate affairs and communications, was one of Chief Executive Officer Dave Ricks's first appointments upon taking the helm of the drugmaker in 2017.

Lilly previously has denied the allegations against Pusey. A Lilly spokesperson on Tuesday declined to comment. Pusey could not be reached.

As part of the resolution, Elling agreed to dismiss the lawsuit, according to a court filing on Monday. The issues were not aired in court, and the terms of the settlement were not disclosed.

"We've resolved things amicably," Elling's attorney Lynne Bernabei told Reuters on Tuesday.

The lawsuit came as other allegations of inappropriate or retaliatory actions by Lilly executives against employees surfaced.

In February, Lilly announced that the company's chief financial officer, Josh Smiley, resigned https://www.reuters.com/business/eli-lilly-says-cfo-resigns-after-inappropriate-communication-with-staff-2021-02-09. Lilly said in a February 9 securities filing that Smiley had engaged in "consensual though inappropriate personal communications" with employees. Smiley has declined to comment.

Reuters reported in March that a former Lilly human resources officer complained https://www.reuters.com/article/us-health-elililly-special-report/special-report-insider-alleges-eli-lilly-blocked-her-efforts-to-sound-alarms-about-u-s-drug-factory-idUSKBN2B31K5 in a legal demand letter that she had been forced out of her job at a New Jersey factory after launching internal investigations alleging various manufacturing lapses. She has not filed a lawsuit against the company.

Lilly has said it encourages individuals to report concerns without fear of retribution.

Elling's lawsuit alleged that she and other women were subjected to sexist comments by Pusey and another senior manager, including that they were "nasty," "bitches," "disruptive," "aggressive," and "rude."

© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo

In 2018, according to the suit, another woman lobbyist at Lilly filed an internal complaint against Pusey, alleging that she had created a hostile workplace and made several offensive comments about Elling and others. Elling corroborated the claims, which a Lilly investigation found to have merit, the lawsuit said.

After that, the lawsuit said, Pusey began to exclude Elling and others who participated in the investigation from briefings of senior leaders and ultimately forced her to resign.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.